UK markets closed

Alnylam Pharmaceuticals, Inc. (ALNY)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
233.85+4.46 (+1.94%)
At close: 04:00PM EDT
233.92 +0.07 (+0.03%)
After hours: 07:40PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close229.39
Bid225.05 x 1200
Ask243.45 x 1000
Day's range228.34 - 236.80
52-week range117.58 - 236.80
Avg. volume990,466
Market cap28.068B
Beta (5Y monthly)0.74
PE ratio (TTM)N/A
EPS (TTM)-7.49
Earnings date26 Oct 2022 - 31 Oct 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est228.45
  • Motley Fool

    Is This Unknown Growth Stock a Buy After Its Blast Off?

    Alnylam Pharmaceuticals' (NASDAQ: ALNY) stock went vertical in the past month -- up over 50% -- and there might be even more growth on the way. Sales of its top-earning medicines are booming, and breakthroughs in clinical trials have added to the enthusiasm. Alnylam has a small handful of medicines on the market, led by its drugs Onpattro and Amvuttra, which are intended to treat peripheral neuropathy caused by hereditary transthyretin amyloidosis (ATTR), which is a rare but deadly and progressively worsening heart disease.

  • Motley Fool

    Why Alnylam Pharmaceuticals Stock Is Vaulting Higher Today

    Shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) are poised to post a new all-time high upon market open Wednesday. The RNA interference (RNAi) drug specialist's stock price rose by as much as 53% in premarket action this morning. Ahead of the opening bell, Alnylam announced that its closely watched phase 3 Apollo-B study of the RNAi therapy, patisiran, in patients with transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy met its primary endpoint of change in baseline in the 6-minute walk test at 12 months compared to placebo.

  • Business Wire

    Alnylam Reports Positive Topline Results from APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy

    CAMBRIDGE, Mass., August 03, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy, met the primary endpoint of change from baseline in the 6-Minute Walk Test (6-MWT) at 12 months compared to placebo (p-value 0.0162). The study also met the first secondary endpoint o